Company:  GERON CORP (GERN)
Form Type:  SC 13G/A
Filing Date:  2/5/2020 
CIK:  0000886744 
Address:  919 EAST HILLSDALE BOULEVARD
SUITE 250
 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  (650) 473-7700 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.54  
Change: 
0.00 (0.00%)  
Trade Time: 
Jun 05  
Market Cap: 
$477.96M
Trade GERN now with 

© 2020  
Description of Business
We are a late-stage clinical biopharmaceutical company that is focused on the development and potential commercialization of imetelstat, an innovative therapeutic for hematologic myeloid malignancies. We have global rights to imetelstat, a first-in-class telomerase inhibitor, which was discovered and developed at Geron. We believe targeting telomerase has the potential to inhibit the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. Data reported from our Phase 2/3 clinical trial in lower risk myelodysplastic syndromes, or MDS, indicate imetelstat may induce meaningful and durable transfusion independence and increases in hemoglobin levels, suggesting potential recovery of normal blood cells occurring in the bone marrow, or hematopoiesis.
Register and access this filing in:     
  FORM SC 13G/A